ASCO-QC 2022 - 2022 ASCO Quality Care Symposium
Sep 30 - Oct 01, 2022 | ChicagoILUS
LARVOL is not affiliated with 2022 ASCO Quality Care Symposium and all trademarks, logos, and brand names are property of their respective owners
Showing 34 abstracts linked to Trials
A randomized controlled trial of routine financial toxicity screening via electronic patient-reported outcomes (AFT-39).
Intervention non-adherence in a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing.
Enrollment patterns and site-level predictors of Black participant recruitment to a multisite randomized clinical trial (RCT) of endocrine therapy adherence support.
An augmented intelligence mobile phone chatbot for medication adherence and toxicity management among patients with gastrointestinal cancers on capecitabine.
12-month secondary outcomes of a prostate cancer survivor symptom self-management intervention.
Carbon emissions and non-biodegradable medical waste generation with alternative dosing strategies.
Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world.
Patient-reported outcomes in a linguistically diverse cancer population: Addressing barriers to access.
Postoperative symptom monitoring with ePROs in an academic public hospital.
Impact of adverse events on independence in daily functioning of older adults with advanced cancer treated with systemic therapy.
Impact of acute toxicities associated with chimeric antigen receptor (CAR) T-cell therapy on health-related quality of life (HRQOL) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
An overview of adverse event (AE) management for patients (pts) receiving abemaciclib.
Investigating keratinocyte growth factor hair serum for the prevention of chemotherapy-induced alopecia.
Number needed to harm (NNH) in patients with non-metastatic, castration-resistant prostate cancer (nmCRPC): A final analysis from the darolutamide (D), enzalutamide (E), and apalutamide (A) clinical trials.
Modifiable risk factors for falls among older adults with advanced cancer.